Cover Image
市場調查報告書

NeuroVive Pharmaceutical AB:產品平台分析

NeuroVive Pharmaceutical AB - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 246033
出版日期 內容資訊 英文 33 Pages
訂單完成後即時交付
價格
Back to Top
NeuroVive Pharmaceutical AB:產品平台分析 NeuroVive Pharmaceutical AB - Product Pipeline Review - 2015
出版日期: 2015年10月14日 內容資訊: 英文 33 Pages
簡介

本報告提供NeuroVive Pharmaceutical AB的治療藥開發平台現狀及各開發階段的比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,彙整最新的企業新聞和發表,後期階段及中止的計劃相關資訊等。

NeuroVive Pharmaceutical AB的基本資料

NeuroVive Pharmaceutical AB概要

  • 主要資訊
  • 企業資料

NeuroVive Pharmaceutical AB:R&D概要

  • 主要的治療範圍

NeuroVive Pharmaceutical AB:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

NeuroVive Pharmaceutical AB:開發中產品概況

  • 最後階段的開發中產品
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

NeuroVive Pharmaceutical AB:藥物簡介

  • cyclosporine
  • NeuroSTAT
  • BC-556
  • NVP-014
  • NVP-015
  • NVP-019

NeuroVive Pharmaceutical AB:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

NeuroVive Pharmaceutical AB:最近的開發平台趨勢

NeuroVive Pharmaceutical AB:暫停中的計劃

NeuroVive Pharmaceutical AB:總公司和子公司的所在地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07655CDB

Summary

Global Markets Direct's, 'NeuroVive Pharmaceutical AB - Product Pipeline Review - 2015', provides an overview of the NeuroVive Pharmaceutical AB's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of NeuroVive Pharmaceutical AB's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of NeuroVive Pharmaceutical AB including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of NeuroVive Pharmaceutical AB's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the NeuroVive Pharmaceutical AB's pipeline products

Reasons to buy

  • Evaluate NeuroVive Pharmaceutical AB's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of NeuroVive Pharmaceutical AB in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the NeuroVive Pharmaceutical AB's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of NeuroVive Pharmaceutical AB and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of NeuroVive Pharmaceutical AB
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of NeuroVive Pharmaceutical AB and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • NeuroVive Pharmaceutical AB Snapshot
    • NeuroVive Pharmaceutical AB Overview
    • Key Information
    • Key Facts
  • NeuroVive Pharmaceutical AB - Research and Development Overview
    • Key Therapeutic Areas
  • NeuroVive Pharmaceutical AB - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • NeuroVive Pharmaceutical AB - Pipeline Products Glance
    • NeuroVive Pharmaceutical AB - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • NeuroVive Pharmaceutical AB - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • NeuroVive Pharmaceutical AB - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • NeuroVive Pharmaceutical AB - Drug Profiles
    • cyclosporine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NVP-014
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NVP-019
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NVP-015
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • NeuroVive Pharmaceutical AB - Pipeline Analysis
    • NeuroVive Pharmaceutical AB - Pipeline Products by Target
    • NeuroVive Pharmaceutical AB - Pipeline Products by Route of Administration
    • NeuroVive Pharmaceutical AB - Pipeline Products by Molecule Type
    • NeuroVive Pharmaceutical AB - Pipeline Products by Mechanism of Action
  • NeuroVive Pharmaceutical AB - Recent Pipeline Updates
  • NeuroVive Pharmaceutical AB - Dormant Projects
  • NeuroVive Pharmaceutical AB - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • cyclosporine
  • NeuroVive Pharmaceutical AB - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • NeuroVive Pharmaceutical AB, Key Information
  • NeuroVive Pharmaceutical AB, Key Facts
  • NeuroVive Pharmaceutical AB - Pipeline by Indication, 2015
  • NeuroVive Pharmaceutical AB - Pipeline by Stage of Development, 2015
  • NeuroVive Pharmaceutical AB - Monotherapy Products in Pipeline, 2015
  • NeuroVive Pharmaceutical AB - Out-Licensed Products in Pipeline, 2015
  • NeuroVive Pharmaceutical AB - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • NeuroVive Pharmaceutical AB - Phase III, 2015
  • NeuroVive Pharmaceutical AB - Phase II, 2015
  • NeuroVive Pharmaceutical AB - Preclinical, 2015
  • NeuroVive Pharmaceutical AB - Discovery, 2015
  • NeuroVive Pharmaceutical AB - Pipeline by Target, 2015
  • NeuroVive Pharmaceutical AB - Pipeline by Route of Administration, 2015
  • NeuroVive Pharmaceutical AB - Pipeline by Molecule Type, 2015
  • NeuroVive Pharmaceutical AB - Pipeline Products by Mechanism of Action, 2015
  • NeuroVive Pharmaceutical AB - Recent Pipeline Updates, 2015
  • NeuroVive Pharmaceutical AB - Dormant Developmental Projects,2015
  • NeuroVive Pharmaceutical AB - Discontinued Pipeline Products, 2015
  • NeuroVive Pharmaceutical AB, Subsidiaries

List of Figures

  • NeuroVive Pharmaceutical AB - Pipeline by Top 10 Indication, 2015
  • NeuroVive Pharmaceutical AB - Pipeline by Stage of Development, 2015
  • NeuroVive Pharmaceutical AB - Monotherapy Products in Pipeline, 2015
  • NeuroVive Pharmaceutical AB - Pipeline by Top 10 Target, 2015
  • NeuroVive Pharmaceutical AB - Pipeline by Top 10 Route of Administration, 2015
  • NeuroVive Pharmaceutical AB - Pipeline by Top 10 Molecule Type, 2015
  • NeuroVive Pharmaceutical AB - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top